Brañes María C, Gillet Raimundo, Valenzuela Rodrigo
Naturalis Research Consortium, Santiago 8700548, Chile.
Department of Nutrition, Faculty of Medicine, University of Chile, Santiago 8380000, Chile.
J Clin Med. 2023 Jan 27;12(3):979. doi: 10.3390/jcm12030979.
No pharmacological treatment is yet approved for non-alcoholic fatty liver disease (NAFLD). Plant sterols have shown healthy properties beyond lowering LDL-cholesterol, including lowering triglycerides and lipoprotein plasma levels. Despite pre-clinical data suggesting their involvement in liver fat control, no clinical study has yet been successful.
Testing a sub-micron, free, phytosterol dispersion efficacy on NAFLD.
A prospective, uncontrolled pilot study was carried out on 26 patients with ≥17.4% liver steatosis quantified by magnetic resonance imaging. Subjects consumed daily a sub-micron dispersion providing 2 g of phytosterols. Liver fat, plasma lipids, lipoproteins, liver enzymes, glycemia, insulinemia, phytosterols, liposoluble vitamins and C-reactive protein were assessed at baseline and after one year of treatment.
Liver steatosis relative change was -19%, and 27% of patients reduced liver fat by more than 30%. Statistically and clinically significant improvements in plasma triglycerides, HDL-C, VLDL and HDL particle number and C-reactive protein were obtained, despite the rise of aspartate aminotransferase, glycemia and insulinemia. Though phytosterol plasma levels were raised by >30%, no adverse effects were presented, and even vitamin D increased by 23%.
Our results are the first evidence in humans of the efficacy of submicron dispersible phytosterols for the treatment of liver steatosis, dyslipidemia and inflammatory status in NAFLD.
目前尚无药物治疗被批准用于非酒精性脂肪性肝病(NAFLD)。植物甾醇已显示出除降低低密度脂蛋白胆固醇之外的健康益处,包括降低甘油三酯和脂蛋白血浆水平。尽管临床前数据表明它们参与肝脏脂肪控制,但尚无临床研究取得成功。
测试亚微米级游离植物甾醇分散体对NAFLD的疗效。
对26例经磁共振成像量化肝脏脂肪变性≥17.4%的患者进行了一项前瞻性、非对照的试点研究。受试者每天服用提供2克植物甾醇的亚微米分散体。在基线和治疗一年后评估肝脏脂肪、血脂、脂蛋白、肝酶、血糖、胰岛素血症、植物甾醇、脂溶性维生素和C反应蛋白。
肝脏脂肪变性相对变化为-19%,27%的患者肝脏脂肪减少超过30%。尽管天冬氨酸转氨酶、血糖和胰岛素血症有所升高,但血浆甘油三酯、高密度脂蛋白胆固醇、极低密度脂蛋白和高密度脂蛋白颗粒数量以及C反应蛋白在统计学和临床上均有显著改善。虽然植物甾醇血浆水平升高>30%,但未出现不良反应,甚至维生素D增加了23%。
我们的结果首次在人体中证明了亚微米级可分散植物甾醇对治疗NAFLD中的肝脏脂肪变性、血脂异常和炎症状态的疗效。